(Total Views: 922)
Posted On: 02/18/2022 12:15:36 AM
Post# of 148878
Re: Cassandra X #118513
While I'm thinking crazy, I think I will float something else.
I believe that Cytodyn is not on the path of a partnership or buyout as most on this board seem to believe.
I believe Cytodyn is on the same coarse they charted out under Pourhassen.
Leronlimab is like a Swiss Army knife and all the the tools work exceptionally well. But you can't separate one from another. Therefore, a partnership with another pharma would be very messy, as any approval will put Leronlimab on the market and, from there, it can be used off label.
The closest you can come to a partnership is to license LL to a pharma with a limited market for all indications. That would work and would give Cytodyn money to proceed forward. (This would leave China out of consideration because they would not limit themselves - they cheat!)
A buyout is still out of the question for the same reasons it has been before - no pharma will pay what we and Cytodyn want for LL.
If Cytodyn was not in the financial pinch it finds itself or if LL had gotten approval for just one indication, we would be on the course set out time and time again for the last two years, at least - to become a big pharma company or, at least, an oncology company.
I believe the present Cytodyn may still be headed for the same goal but by different means, saner means. No more Fife, no more doing the quick and dirty trials, counting on EUAs, no more low-rent lawyers, no more crappy CROs. Short cuts have always hurt us.
As I see it, finances are our biggest vulnerability but, as we have seen with this Welch deal, we are not without options. We need some very smart people around Cytodyn and it seems to have some. We can thank our miracle drug for that! Let's hope they give damn about the shareholders and have good cause to! Fight the FUD!
I believe that Cytodyn is not on the path of a partnership or buyout as most on this board seem to believe.
I believe Cytodyn is on the same coarse they charted out under Pourhassen.
Leronlimab is like a Swiss Army knife and all the the tools work exceptionally well. But you can't separate one from another. Therefore, a partnership with another pharma would be very messy, as any approval will put Leronlimab on the market and, from there, it can be used off label.
The closest you can come to a partnership is to license LL to a pharma with a limited market for all indications. That would work and would give Cytodyn money to proceed forward. (This would leave China out of consideration because they would not limit themselves - they cheat!)
A buyout is still out of the question for the same reasons it has been before - no pharma will pay what we and Cytodyn want for LL.
If Cytodyn was not in the financial pinch it finds itself or if LL had gotten approval for just one indication, we would be on the course set out time and time again for the last two years, at least - to become a big pharma company or, at least, an oncology company.
I believe the present Cytodyn may still be headed for the same goal but by different means, saner means. No more Fife, no more doing the quick and dirty trials, counting on EUAs, no more low-rent lawyers, no more crappy CROs. Short cuts have always hurt us.
As I see it, finances are our biggest vulnerability but, as we have seen with this Welch deal, we are not without options. We need some very smart people around Cytodyn and it seems to have some. We can thank our miracle drug for that! Let's hope they give damn about the shareholders and have good cause to! Fight the FUD!
(7)
(0)Scroll down for more posts ▼
